Skip to main content

Table 1 Demographic characteristic of CML patients responsive and non-responsive to imatinib therapy and blood donors

From: Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Characteristic Imatinib Responsive Group (n = 30) Imatinib Non-Responsive Group (n = 28) Control Group (n = 28)
Ethnicity:
 Malays 13 (43%) 16 (57%) 15 (53%)
 Chinese 12 (40%) 7 (25%) 10 (36%)
 Indians 5 (17%) 5 (18%) 3 (11%)
Gender:
 Male 17 (57%) 13 (46%) 22 (79%)
 Female 13 (43%) 15 (54%) 6 (21%)
Age (year):
 18 - < 45 13 (43%) 11 (39%) 22 (79%)
  ≥ 45 17 (57%) 17 (61%) 6 (21%)
Mean ± std. dev 48 ± 13 46 ± 14 36 ± 9